10.29.26 -- What's Being Overlooked In Biopharma Manufacturing?

Two products made in the same facility can carry materially different carbon footprints, yet traditional accounting methods can't see the difference. This whitepaper details how product-level carbon footprinting resolves that blind spot and reshapes supply chain decision-making in biopharma.

Paper-based environmental monitoring documentation creates measurable compliance risk and administrative burden at scale. This whitepaper examines the technical and organizational factors that determine whether a paperless EM system delivers on its promise.

Because conjugation creates a new molecular entity with its own stability profile, ADC formulation strategies built on mAb experience can miss critical risks, from buffer exchange-induced aggregation to photosensitivity that emerges only in the conjugated form.